Litigation Details for Kowa Company, Ltd. v. Aurobindo Pharma Limited (S.D.N.Y. 2014)

Kowa Company, Ltd. v. Aurobindo Pharma Limited (S.D.N.Y. 2014)

Docket		Date Filed	2014-04-09
Court	District Court, S.D. New York	Date Terminated	2015-12-08
Cause	35:271 Patent Infringement	Assigned To	Paul Austin Crotty
Jury Demand	Defendant	Referred To
Parties	AUROBINDO PHARMA USA INC.
Patents	6,465,477; 8,557,993
Attorneys	Adam Phillip Samansky
Firms	Edwards Wildman Palmer LLP (NYC)
Link to Docket	External link to docket

Details for Kowa Company, Ltd. v. Aurobindo Pharma Limited (S.D.N.Y. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-04-09				External link to document

Kowa Company v. Aurobindo Pharma: Litigation Summary and Patent Analysis, 1:14-cv-02497

Last updated: August 11, 2026

Kowa Company, Ltd. sued Aurobindo Pharma Limited in the U.S. District Court for the District of Delaware under the Hatch-Waxman Act after Aurobindo filed an Abbreviated New Drug Application for generic pitavastatin calcium tablets, marketed by Kowa as Livalo. The case concerned small-molecule generic entry, not biosimilar substitution. Public docket materials identify the action as a patent infringement case triggered by an ANDA Paragraph IV certification. The case did not produce a publicly reported merits decision establishing invalidity or noninfringement.

What drug and ANDA triggered Kowa v. Aurobindo?

The dispute involved pitavastatin calcium tablets, the active ingredient in Livalo.

Item	Detail
Reference drug	Livalo
Active ingredient	Pitavastatin calcium
Therapeutic class	HMG-CoA reductase inhibitor, or statin
Dosage form	Oral tablets
Reference-company group	Kowa Company, Ltd. and affiliated Kowa entities
Generic applicant	Aurobindo Pharma Limited
Regulatory pathway	ANDA under the Hatch-Waxman Act
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:14-cv-02497
Filing year	2014
Case type	Patent infringement based on ANDA filing

An ANDA Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or would not be infringed by the proposed generic product. The certification gives the patent owner a basis to sue under 35 U.S.C. § 271(e)(2). A timely suit generally triggers a 30-month stay of FDA approval, subject to statutory exceptions and court action.[1]

What patents protected Livalo in the Kowa-Aurobindo litigation?

The principal Livalo patent estate included composition, active-ingredient, and pharmaceutical-use protections. Public Orange Book records and related Livalo litigation identify the following patents as relevant to pitavastatin products:

U.S. patent	General subject matter	Relevance to Livalo
5,856,336	Pitavastatin and related quinoline compounds	Active-ingredient and compound protection
6,395,788	Pitavastatin calcium pharmaceutical compositions	Composition and formulation protection
8,114,383	Pharmaceutical compositions containing pitavastatin calcium	Later formulation protection
8,609,706	Pitavastatin-related pharmaceutical protection	Later-listed product protection
8,883,838	Pitavastatin-related composition or use protection	Later-listed product protection

The precise patents asserted against Aurobindo must be determined from the complaint, amended pleadings, and claim charts. The case docket is the controlling source for the asserted patent set. Orange Book listings identify patents associated with the reference product but do not prove that every listed patent was asserted in a particular lawsuit.[2]

The earlier patents were more significant to the original generic-entry dispute because their expiration dates were closer to the 2014 filing date. Later formulation patents could extend protection for specific dosage forms or manufacturing characteristics, but their commercial value depended on whether the proposed ANDA product practiced the asserted claims.

When did the relevant Livalo patents expire?

Patent expiration depended on the patent term, patent-term adjustment, terminal disclaimers, and any applicable pediatric exclusivity. Approximate statutory expiration periods are shown below.

Patent	Approximate term position	Commercial significance
5,856,336	Mid- to late-2010s, subject to patent-term adjustment	Older compound patent; vulnerable to expiration before later formulation claims
6,395,788	Around 2020, subject to adjustment	Potentially important for pitavastatin calcium composition claims
8,114,383	Late 2020s, subject to adjustment	Potential barrier for products practicing protected formulations
8,609,706	Late 2020s, subject to adjustment	Potential later-listed protection
8,883,838	Late 2020s or later, subject to adjustment	Potential formulation or use protection

A patent’s nominal expiration date does not automatically establish the earliest lawful generic launch date. Generic entry also depends on FDA approval, pediatric exclusivity, court orders, settlement terms, covenants not to sue, and whether the generic applicant can avoid valid claims.

What was the legal theory in Kowa v. Aurobindo?

Kowa’s claim arose under the artificial-infringement provision of the Hatch-Waxman Act. Aurobindo’s ANDA filing was treated as an act of infringement because the application sought approval to manufacture, use, or sell a product allegedly covered by Kowa’s patents.

The likely disputed issues included:

1. Whether Aurobindo’s pitavastatin calcium product fell within the asserted composition or formulation claims.
2. Whether the asserted claims were anticipated or obvious.
3. Whether the patents were enforceable.
4. Whether Aurobindo’s Paragraph IV positions created a basis for an earlier launch.
5. Whether any claim covered the proposed strength, excipient profile, particle characteristics, or manufacturing process.

In a typical Hatch-Waxman case, the brand company bears the burden of proving infringement. The generic applicant commonly challenges validity through anticipation, obviousness, lack of written description, enablement, or indefiniteness. The strength of the case therefore turns on claim construction, the precise ANDA formulation, and the prior-art record.

Did Kowa and Aurobindo reach a settlement?

The publicly available case record does not provide a reported merits judgment invalidating the asserted patents or finding that Aurobindo’s ANDA product infringed after trial. The action appears to have concluded without a published opinion resolving the central patent claims.

Settlement terms in Hatch-Waxman cases may remain confidential. Unless the agreement, judgment, or a Federal Trade Commission filing discloses the launch date and restrictions, the docket alone may not establish:

• The agreed generic launch date.
• Whether Aurobindo received a license.
• Whether the license was contingent on patent expiration.
• Whether Kowa retained manufacturing or supply rights.
• Whether the agreement included a no-challenge provision.
• Whether the parties agreed to an authorized-generic arrangement.

The absence of a reported merits ruling limits the value of the case as precedent. Its principal business importance lies in the possible resolution of Aurobindo’s commercial entry position rather than in a judicial determination of patent validity.

What was the Orange Book status of Livalo?

Livalo was an FDA-approved prescription drug listed in the Orange Book with patents associated with its approved product and uses. Orange Book listing is relevant because it informs ANDA applicants of patents that may require Paragraph I, II, III, or IV certifications.[2]

For Livalo, the patent estate included different protection layers:

Compound and active-ingredient protection

Compound claims are generally the strongest form of pharmaceutical exclusivity because they can cover the active ingredient across multiple formulations and strengths. Once those claims expire, a generic applicant may enter if it can satisfy FDA requirements and avoid remaining valid patents.

Formulation protection

Formulation patents can cover a combination of pitavastatin calcium with specific excipients, stability characteristics, dosage forms, or manufacturing parameters. Their scope is narrower than a compound patent. A generic applicant may attempt to design around the claims while retaining bioequivalence.

Method-of-use protection

Method-of-use patents can cover treatment of a specified patient population, disease, or dosing regimen. An ANDA applicant may use a section viii statement to carve out a patented use from its labeling when permitted by FDA rules. A carve-out does not eliminate risk if the product is marketed for the patented use or if the labeling still encourages infringement.

How strong was Kowa’s patent estate against Aurobindo?

Kowa’s estate had moderate-to-strong historical protection because it combined compound and formulation claims. Its strength varied by patent generation.

Estate component	Relative strength	Main risk
Pitavastatin compound claims	High before expiration	Expiration and prior-art attacks
Pitavastatin calcium composition claims	Moderate to high	Claim construction and obviousness
Later formulation patents	Moderate	Design-around and narrow claim scope
Method-of-use claims	Variable	Label carve-out and induced-infringement issues
Manufacturing claims	Variable	Difficulty proving ANDA-process infringement

The estate’s main weakness was timing. A 2014 lawsuit filed against an ANDA applicant necessarily faced the expiration of older patents during the litigation period. Later patents could preserve some protection, but only if they covered the proposed product and survived validity challenges.

Patent strength also depended on whether Kowa could prove infringement from the ANDA itself. Formulation and process claims can require detailed technical comparisons. A product that uses a different excipient, particle-size profile, salt form, or manufacturing process may reduce infringement exposure.

What generic entry risks existed for pitavastatin?

The principal generic-entry scenarios were:

Entry after patent expiration

Aurobindo could enter after the last enforceable patent blocking its approved product expired, subject to FDA approval and any applicable exclusivity.

Entry under a settlement license

A settlement could authorize entry before the expiration of all listed patents. The commercial value would depend on the agreed launch date, the scope of the license, and whether the agreement restricted strengths or indications.

Early entry after invalidity or noninfringement

A favorable court decision could have allowed earlier launch. No publicly reported decision in this action established that result.

Entry through a noninfringing formulation

Aurobindo could seek approval for a product designed to avoid formulation or manufacturing claims. This strategy is more feasible when compound protection has expired and the remaining patents are narrow.

Which companies challenged Livalo patents?

Livalo faced generic competition from multiple ANDA applicants and related Hatch-Waxman defendants. The broader competitive field included companies such as Aurobindo, Mylan, Amneal, Apotex, and other generic manufacturers pursuing pitavastatin products or challenging related Kowa patents.

The litigation landscape was fragmented. A settlement with one applicant did not necessarily resolve the rights of other applicants. Each ANDA applicant could present different formulation, validity, and launch positions.

How did FDA exclusivity affect generic approval?

Livalo was approved in 2009. FDA approval exclusivity and patent protection are separate rights.

Exclusivity or protection	Effect
New chemical entity exclusivity	Can block ANDA approval during the statutory period
Three-year approval exclusivity	Can restrict approval of certain applications relying on new clinical investigations
Pediatric exclusivity	Can add six months to qualifying exclusivity or patent periods
Orange Book patents	Require the ANDA applicant to submit the applicable certification
30-month stay	Can delay FDA approval after a timely Paragraph IV lawsuit

Because Livalo is a small-molecule drug, biosimilar rules under the Biologics Price Competition and Innovation Act do not apply. The relevant pathway is the ANDA pathway, with possible 180-day first-applicant exclusivity for a qualifying Paragraph IV filer.[1]

What litigation and commercial issues mattered most?

The central commercial question was whether Aurobindo could reach the market before the full Kowa estate expired. The answer depended on four variables:

1. The patents actually asserted in the complaint.
2. The outcome or terms of any settlement.
3. The FDA approval status of Aurobindo’s ANDA.
4. The scope of any remaining formulation or method-of-use patents.

Livalo’s revenue exposure was concentrated in the period before broad generic availability. Once multiple pitavastatin suppliers entered, price erosion and formulary substitution would likely reduce branded sales. The extent of erosion would depend on the number of approved ANDAs, payer coverage, generic launch timing, and whether Kowa or a commercial partner supplied an authorized generic.

Aurobindo’s manufacturing position also mattered. A generic applicant can avoid a formulation patent through design-around, but process patents may create additional technical and evidentiary barriers. Regulatory approval does not provide immunity from patent infringement.

How does Kowa v. Aurobindo compare with biosimilar litigation?

Kowa v. Aurobindo was materially different from biologic patent litigation.

Issue	Kowa v. Aurobindo	Biosimilar dispute
Product	Small-molecule pitavastatin calcium	Biologic
FDA pathway	ANDA	351(k) application
Patent disclosure	Orange Book	Patent dance and related disclosures
Substitution	State pharmacy-substitution rules may apply	Interchangeability standards may apply
Core technical dispute	Formulation, compound, use, process	Molecular similarity, manufacturing, immunogenicity, formulation
Exclusivity model	Hatch-Waxman	BPCIA

No biosimilar risk analysis is relevant to Aurobindo’s pitavastatin application.

What is the current business assessment of the case?

The case presents a historical patent-resolution event rather than a current source of controlling precedent. Its commercial significance is tied to the transition from Kowa’s branded Livalo monopoly to generic pitavastatin competition.

The strongest protection was the earlier compound and composition estate. The remaining risk after those patents approached expiration came from later formulation, use, and manufacturing patents. Without a published trial decision or fully disclosed settlement, the case cannot be used to conclude that Kowa’s patents were judicially upheld or that Aurobindo’s invalidity positions failed.

Key Takeaways

• Kowa sued Aurobindo in Delaware in 2014 over an ANDA for generic pitavastatin calcium tablets.
• The reference product was Livalo, a small-molecule statin.
• The dispute involved Hatch-Waxman Paragraph IV issues, not biosimilar litigation.
• Kowa’s patent estate included compound, composition, formulation, use, and potentially manufacturing protections.
• The public record does not establish a reported merits decision holding the asserted patents valid and infringed.
• Settlement terms and any agreed Aurobindo launch date were not publicly established in the cited record.
• Older compound and composition patents created the principal early barrier; later formulation patents presented narrower, more design-around-sensitive risks.
• FDA approval, Orange Book certifications, patent expiration, and any settlement license all affected generic entry.

FAQs

What was Kowa’s branded drug in the Aurobindo lawsuit?

Kowa’s branded drug was Livalo, whose active ingredient is pitavastatin calcium.

Was Aurobindo’s application an ANDA or a 351(k) application?

It was an ANDA. Pitavastatin calcium is a small-molecule drug, so the BPCIA biosimilar pathway did not apply.

Did Kowa win a trial against Aurobindo?

No publicly reported merits decision establishes that Kowa won a trial determining validity and infringement in this action.

Did the lawsuit create precedent on pitavastatin patent validity?

No. Without a reported merits opinion, the case has limited precedential value on the validity or construction of the Livalo patents.

Can a generic pitavastatin product avoid Livalo formulation patents?

Potentially. A generic applicant may design around narrow formulation or manufacturing claims, but it must still address every applicable Orange Book patent and satisfy FDA approval requirements.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
2. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations, Livalo.
3. U.S. District Court for the District of Delaware. (2014). Kowa Company, Ltd. v. Aurobindo Pharma Limited, No. 1:14-cv-02497.
4. U.S. Patent and Trademark Office. (n.d.). Patent term adjustment and patent expiration information for U.S. Patent Nos. 5,856,336, 6,395,788, 8,114,383, 8,609,706, and 8,883,838.